Overcoming challenges in determining antibody binding rate constants on cells: a new assay on the horizon?
The development of a novel assay to calculate the kinetic binding parameters of up to 30 antibodies simultaneously to living cells.
Characterizing the properties controlling an antibody-receptor interaction—such as the kinetic rate constants and affinity—is a critical step during drug discovery. Cell-based methods can be used due to their physiological relevance. However, current assays may require long incubation times, lack kinetic information and require labeling. We developed a label-free assay to determine ka, kd and KD of up to 30 antibodies on live cells. This method is amenable to human IgG or rabbit IgG antibodies and all cell types. Finally, we will discuss the advantages of implementing this method at early stages of the screening cascade.
What will you learn?
- Limitations of current pre-equilibrium methods to determine kinetic rate constants of antibody-receptor interactions on cells
- Details of a novel method to determine kinetic rate constants of unlabeled antibodies to cells
- How an automated microfluidic method can accelerate selection of lead candidates for preclinical studies
Who this may interest?
- Bioanalytical scientists and drug development scientists involved in the development of monoclonal antibody-based therapeutics
- Group leaders or Director-level scientists responsible for workflow, productivity and efficiencies
Speakers
Jasmine Singh
Application Scientist
Gyros Protein Technologies (Uppsala, Sweden)
Jasmine is currently a Field Application Scientist at Gyros Protein Technologies (Uppsala, Sweden) and has been with the company since May of 2022. Prior to her current position, Jasmine worked as an Application Scientist for a small startup in the Bay Area where she assisted her customers in developing protocols for immunoassays in various application areas ranging from oncology to neuroscience. Jasmine received her Master of Science in Biochemistry from the University of Colorado (CO, USA) and has spent her career evaluating the ways in which technology and immunoassays can be used to answer crucial scientific questions.
Eric Janezic
Principal Scientist
Genentech (CA, USA)
Eric obtained his PhD in Pharmacology from the University of Washington (WA, USA), studying the regulation of GPCR trafficking. In 2021, he joined the Biochemical and Cellular Pharmacology department at Genentech (CA, USA), where he leads a lab responsible for determining biophysical parameters controlling the interactions of therapeutic candidates on living cells for projects across early- and late-stage research portfolios. In this capacity, Eric is passionate about evaluating and implementing cutting-edge technologies that will address complex challenges in his field of expertise.
This webinar was recorded on Thursday 31 October 2024
In association with
